Child development following in utero exposure: levetiracetam vs sodium valproate.

R Shallcross, R L Bromley, B Irwin, L J Bonnett, J Morrow, G A Baker, Alan Fryer (Collaborator), Rachel Kneen (Collaborator), Siddharth Banka (Collaborator), Maria Briggs (Collaborator), Jill Clayton-Smith (Collaborator), George Mawer (Collaborator), Gus Baker (Collaborator), Rebecca Bromley (Collaborator), Pete Dixon (Collaborator), Alison Gummery (Collaborator), Rebekah Shallcross (Collaborator), Loretta Kerr (Collaborator), John Craig (Collaborator), Stephen Hunt (Collaborator)Beth Irwin (Collaborator), Patrick Morrison (Collaborator), James Morrow (Collaborator), Norman Delanty (Collaborator), Brenda Liggan (Collaborator), Aline Russell (Collaborator), Henry Smithson (Collaborator), Linda Parsons (Collaborator), Iain Robertson (Collaborator)

Research output: Contribution to journalArticlepeer-review

40 Downloads (Pure)


OBJECTIVE: Children born to women with epilepsy (WWE), exposed in utero to levetiracetam (LEV, n = 51), were assessed for early cognitive development and compared to children exposed to sodium valproate in utero (VPA, n = 44) and a group of children representative of the general population (n = 97). METHODS: Children were recruited prospectively from 2 cohorts in the United Kingdom and assessed using the Griffiths Mental Development Scale (1996), aged
Original languageEnglish
Pages (from-to)383-389
Number of pages6
Issue number4
Publication statusPublished - 25 Jan 2011


Dive into the research topics of 'Child development following in utero exposure: levetiracetam vs sodium valproate.'. Together they form a unique fingerprint.

Cite this